Efficacy of oral AB070597 for the management of chronic kidney disease in cats: a prospective, randomised, controlled parallel-group study.

Abstract

Objectives: It has been reported that AB070597, which contains amino acids and peptides, may prevent the progression of chronic kidney disease (CKD) in cats. The aim of this study was to evaluate the effect of AB070597 on CKD in International Renal Interest Society (IRIS) stage 2 or 3 cats compared with a placebo.

Methods: A prospective, randomised, controlled parallel-group study was conducted on 35 cats with CKD. The cats were randomly allocated to receive 300 mg of AB070597 or placebo for 180 days, and cats were re-examined every 30 days. Changes in the results were compared from baseline to endpoint in each group, and the efficacy of AB070597 in cats with CKD was assessed.

Results: A total of 35 cats met the inclusion criteria, of which 20 received AB070597 and 15 received a placebo. Blood urea nitrogen (BUN), creatinine (Cre) and phosphorus levels increased significantly in the placebo group at 180 days compared with those at baseline, 30 days and 60 days, whereas these values were not significantly changed in the AB070597 group during the study period. The IRIS stage was also stable in cats with AB070597 from the baseline to the end of the study, whereas the IRIS stage progressed from stage 2 to stage 3 in 26% of cats with placebo. Body weight did not change significantly in either group.

Conclusions and relevance: The administration of AB070597 in cats with CKD may be effective in preventing CKD progression.